Author:
Rothschild Anthony J.,Mahableshwarkar Atul R.,Jacobsen Paula,Yan Mingjin,Sheehan David V.
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology
Reference30 articles.
1. Alvarez, E., Perez, V., Dragheim, M., Loft, H., Artigas, F., 2011. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in subjects with major depressive disorder. Int. J. Neuropsychopharmacol. (July 18) 1–12 [Epub ahead of print].
2. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR);American Psychiatric Association,2000
3. Evidence-based pharmacological treatment of generalized anxiety disorder;Baldwin;Int. J. Neuropsychopharmacol.,2011
4. Baldwin D.S., Loft H., Dragheim M., 2011b. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur. Neuropsychopharmacol. (December 29) [Epub ahead of print] doi:10.1016/j.euroneuro.2011.11.008.
5. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004 ): a novel multimodal compound for the treatment of major depressive disorder;Bang-Andersen;J. Med. Chem.,2011
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献